Near patient testing in exceptional situations;Patientennahe diagnostik in krisensituationen

LaboratoriumsMedizin

Volumn 30, Issue 4, 2006, Pages 211-218

  Friedewald, Steifen ^a   Finke, Ernst Jürgen ^a   Dobler, Gerhard ^a  

^a BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

Author keywords

B agents; Bioterrorism; Influenza; Pandemic; Rapid test

Indexed keywords

BIOLOGICAL WARFARE; EPIDEMIC; GERMANY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; IMMUNOFLUORESCENCE; INFLUENZA; LABORATORY TEST; MEDICAL CARE; MICROBIOLOGICAL EXAMINATION; POINT OF CARE TESTING; PREVALENCE; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION;

EID: 33748514544     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2006.036     Document Type: Review

References (20)

1. Normenentwurf DIN EN ISO 22870: Patientennahe Untersuchungen (Point-of-Care Testing, POCT) - Anforderungen an Qualität und Kompetenz (ISO/DIS 22870:2004); Deutsche Fassung: prEN ISO 22870:2004.
2. Christ-Grain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:601.
3. Kost GJ. Preventing medical errors in point-of-care testing - security, validation, performance, safeguards, and connectivity. Arch Pathol Lab Med 2001;125:1307-15.
4. Schlüter B, Junker R. Schneller ist nicht immer besser. Dtsch Ärztebl 2003;100:A87-9.
5. Jahn UR, Van Aken H. Near-patient testing - point-of-care or point of costs and convenience? B J Anaesthesia 2003;90:425-7.
6. Müller M. Laboruntersuchungen in der ärztlichen Praxis. Der Allgemeinarzt 2006;28:44-7.
7. Bales S, Baumann HG, Schnitzler N. Infektionsschutzgesetz. Kommentar und Vorschriftensammlung. 2. überarbeitete Auflage. Stuttgart: Verlag W. Kohlhammer 2003.
8. Fock R, Koch U, Finke EJ, Niedrig M, Wirtz A, Peters M, et al. Schutz vor lebensbedrohenden importierten Infektionskrankheiten: Strukturelle Erfordernisse bei der Behandlung von Patienten und anti-epidemische Maßnahmen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2000;43:891-9.
9. Madjid M, Lillibridge S, Mirhaji P, Casscells W. Influenza as a bioweapon. J R See Med 2003;96:345-6.
10. Steininger C, Kundi M, Aberle SW, Aberle JH, Popow-Kraupp T. Effectiveness of reverse transcription-PCR, virus isolation and enzyme-linked immunosorbent assay for the diagnosis of influenza A virus infection in different age groups. J Clin Microbiol 2002;40:2051-6.
11. Apisarnthanarak A, Kitphati R, Thongphubeth K, Patoomanunt P, Anthanont P, Auwanit W, et al. Atypical avian influenza (H5N1). Emerg Infect Dis 2004;10:1321-4.
12. HHS Pandemic Influenza Plan: Supplement 2 Laboratory Diagnostics. www.pandemicflu.gov
13. Anderson A, Eisold JF. Anthrax attack at the U.S. Capitol. Front Line thoughts. AAOHN Journal 2002;50:170-3.
14. Byrne KM, Fruchey IR, Bailey AM, Emanuel PA. Automated biological agents testing systems. Expert Rev of Molec Diagn 2003;3:759-68.
15. Biological Detection System Technologies Technology and Industrial BaseStudy. Internet: http://stinet.dtic.mil/cgi-bin/GetTRDoc?AD = A438853&Location = U2&doc = GetTR Doc.pdf
16. Liu RH, Yang J, Lenigk R, Bonanno J, Grodzinski P. Self-contained fully integrated biochip for sample prep, PCR and DNA microarray detection. Anal Chem 2004;76:1824-31.
17. Zuiderwijk M, Tanke HJ, Sam Niedbala R, Corstjens PL. An amplification-free hybridization based DNA assay to detect S. pneumoniae utilizing the up-converting phosphor technology. Clin Biochem 2003;36:401-3.
18. French DJ, Archard CL, Anderson MT, McDowell DG. Ultra-rapid DNA analysis using HyBeacon and direct PCR amplification from saliva. Mol Cell Probes 2002;16:319-26.
19. Lim DV, Simpson JM, Kearns EA, Kramer MF. Current and developing technologies for monitoring agents of bioterrorism and biowarfare. Clin Microbiol Rev 2005;18:583-607.
20. Richtline der Europäischen Union 98/79/EG (auch unter IVDD-In vitro diagnostic directive bekannt).